06th week of 2009 patent applcation highlights part 51 |
Patent application number | Title | Published |
20090036468 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS - The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of treating depression using dopamine receptor ligands. | 2009-02-05 |
20090036469 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS - The present invention is directed to a compound of formula (I), | 2009-02-05 |
20090036470 | PALIPERIDONE DERIVATIVES - A compound of formula (1) is useful as a pharmaceutical and as an intermediate in making paliperidone. | 2009-02-05 |
20090036471 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors - This invention concerns compounds of formula | 2009-02-05 |
20090036472 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS - The present invention relates to novel azabicyclo derivatives of Formula (I) as anti-inflammatory agents which are useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis. | 2009-02-05 |
20090036473 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE - This invention relates to novel quinazolinone derivatives having medical utility, to use of the quinazolinone derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinazolinone derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of K | 2009-02-05 |
20090036474 | Quinazoline derivatives for use against cancer - The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R | 2009-02-05 |
20090036475 | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use - This invention relates to novel potassium channel modulating agents, and their use in the preparation of pharmaceutical compositions. | 2009-02-05 |
20090036476 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX - This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. | 2009-02-05 |
20090036477 | Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors - This invention relates to novel 3-aza-spiro[5.5]undec-8-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2009-02-05 |
20090036478 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I | 2009-02-05 |
20090036479 | METHOD OF INHIBITING CHOROIDAL NEOVASCUARIZATION - The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents. | 2009-02-05 |
20090036480 | 5-Ht7 Receptor Antagonists - The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders. | 2009-02-05 |
20090036481 | Novel Azaindole Inhibitors of Mtp and Apob - The present invention relates to 7-azaindole-based compounds, to processes for the preparation thereof, to pharmaceutical compositions comprising them, and to the use thereof in the preparation of medicaments that are useful as inhibitors of MTP and of ApoB secretion. | 2009-02-05 |
20090036482 | Imidazopyridine-derivatives as inductible no-synthase inhibitors - The compounds of Formula (I) | 2009-02-05 |
20090036483 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS - The invention provides novel quinolinone-carboxamide 5-HT | 2009-02-05 |
20090036484 | Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments - A compound of formula (I): (I), or a pharmaceutically acceptable salt thereof; for use as a medicament (for example modulating the glucocorticoid receptor in a warm blooded animal), and pharmaceutical compositions comprising such compounds. | 2009-02-05 |
20090036485 | Quinoline derivatives - The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R | 2009-02-05 |
20090036486 | COMPOSITION - The invention relates to the use of 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one for preparing a medicament intended to prevent or treat inflammatory disorders. | 2009-02-05 |
20090036487 | Combinations - The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred AChE inhibitors are donepezil (Aricept®), tacrine (Cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil. | 2009-02-05 |
20090036488 | RECURRENCE PREVENTIVE THERAPEUTIC AGENT FOR PSYCHOSTIMULANT-INDUCED PSYCHOSIS AND SCHIZOPHRENIA - The present invention provides a therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia. This therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia includes a drug that amplifies serotonin signals as an active component. This therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia includes a drug that amplifies serotonin signals as an active component. This therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia includes a drug that amplifies serotonin signals as an active component. | 2009-02-05 |
20090036489 | Novel Cyclic Aminophenylalkanoic Acid Derivative - The present invention provides cyclic aminophenylalkanoic acid derivatives that act as agonists for human peroxisome proliferator-activated receptors (PPARs), in particular human PPARα isoform, and are effective in the treatment of abnormal lipid metabolism, diabetes and other disorders. The present invention also provides addition salts of such cyclic aminophenylalkanoic acid derivatives and pharmaceutical compositions containing these compounds. | 2009-02-05 |
20090036490 | Controlled delivery system - The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. | 2009-02-05 |
20090036491 | Transdermal pharmaceutical delivery compositions - A pharmaceutically delivery system and method of use therefor are described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent. | 2009-02-05 |
20090036493 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex - This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. | 2009-02-05 |
20090036494 | Administration of Pharmaceuticals - A new administration regimen giving an extended plasma concentration profile of a H | 2009-02-05 |
20090036495 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists - The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain. | 2009-02-05 |
20090036497 | ECTOPARASITE CONTROL METHOD - This invention relates to a method of controlling or preventing infestations of ectoparasites, preferably hematophageous ectoparasites, on an animal by administering to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, or an N-oxide, or a pharmaceutically or veterinarily acceptable salt thereof, | 2009-02-05 |
20090036498 | FLY CONTROL METHOD - This invention relates to a method of treating myiasis of an animal by applying to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, an N-oxide or a pharmaceutically or veterinarily acceptable salts salt thereof | 2009-02-05 |
20090036499 | FLY CONTROL METHOD - This invention relates to a method of controlling or preventing infestations of flies on an animal by applying to the animal a composition comprising an parasiticidally effective amount of a compound of Formula 1, (3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide), or an N-oxide, or a salt thereof, | 2009-02-05 |
20090036500 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR - An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night. | 2009-02-05 |
20090036501 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha - 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-α or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-α or PDE4. | 2009-02-05 |
20090036502 | Thiadiazole Compounds and Uses Thereof - Thiadiazole compounds, compositions, bioconjugates, and methods for targeting and photoactivation at target sites. | 2009-02-05 |
20090036503 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 - Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM. | 2009-02-05 |
20090036504 | 2-Aminoethoxyacetic Acid Derivatives and Their Use - The present application relates to novel 2-aminoethoxyacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders. | 2009-02-05 |
20090036505 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof - The invention discloses imidazole-5-carboxylic acid derivatives, and their preparation methods. The derivatives of the invention are Angiotensin II receptor antagonists with angiotensin II antagonistic activity and antihypertensive activity, and thereby can be used as a therapeutical agent to treat hypertension. | 2009-02-05 |
20090036506 | 5-Iodotetrazoles - The compounds of the formula (I) | 2009-02-05 |
20090036507 | BIS (CYANOPHENYL) METHYL-TRIAZOLE FOR USE IN PREVENTION OF BREAST CANCER - The present invention relates to the use of a lower dosage of bis(cyanophenyl)methyl-triazole of the formula (I) or a pharmaceutically acceptable salts thereof, for the preparation of a pharmaceutical composition for the prevention of conditions responsive to aromatase inhibition and to inhibition of estrogen biosynthesis, especially breast cancer, in mammals. | 2009-02-05 |
20090036508 | AMINO INDAZOLE DERIVATIVES - Compounds of the formula I | 2009-02-05 |
20090036509 | N-(Ortho-Phenyl)-1-Methyl -3-Trifluoromethlpyrazole-4-Carboxanilides and Their Use as Fungicides - The present invention relates to N-(ortho-phenyl)-1-methyl-3-trifluoromethylpyrazole-4-carboxanilides of the formula I | 2009-02-05 |
20090036510 | 1, 2-DIARYL PYRAZOLES USEFUL AS ANALGETIC AND ANTIINFLAMMATORY AGENTS - The present invention relates to new compounds of formula (I), (I) wherein the meaning of R | 2009-02-05 |
20090036511 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders. | 2009-02-05 |
20090036512 | FUNGICIDAL ACTIVE COMPOUND COMBINATION - Active compound combinations comprising an oxime ether derivative of the formula (I) and captan and their use as fungicides are described. | 2009-02-05 |
20090036513 | Antiviral Drugs for Treatment of Arenavirus Infection - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). | 2009-02-05 |
20090036514 | Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury - The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke. | 2009-02-05 |
20090036515 | METHOD FOR TREATING COLONIC VISCEROSENSITIVITY AND SPASTICITY - There is provided a method of treating colonic viscerosensitivity and spasticity induced by a colonic examination chosen from colonic endoscopy and of barium/air contrast colonic radiography and virtual colonoscopy. The method comprises prescribing and/or administering to a patient in need thereof a pharmaceutically effective oral, sub-lingual, nasal or transdermic dose of a non-centrally-acting opioid agonist for a period of at least two days before the colonic examination. | 2009-02-05 |
20090036516 | COMPOUNDS FOR TREATING METABOLIC SYNDROME - Compounds of general formula: | 2009-02-05 |
20090036517 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE - The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions. | 2009-02-05 |
20090036518 | PHARMACEUTICAL COMPOSITION CONTAINING FLAVONOIDS - A pharmaceutical composition is provided, where the pharmaceutical composition contains formula (I), (II), or (III) flavonoids which possess (PDE4), as a main ingredient. Especially, this composition has a binding affinity of high affinity rolipram binding sites (HARBS) of a PDE4 lower than a binding affinity of low affinity rolipram binding sites (LARBS) of the PDE4 is used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), or chronic inflammation, and has bronchodilatory effects. In addition, whether the above-mentioned flavonoids have side effects, such as nausea, vomiting, gastric hypersecretion, etc., in accordance with their binding affinity to HARBS of particulates of brain cells are disclosed. | 2009-02-05 |
20090036519 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGAND AND PROCESS FOR PRODUCING THE SAME - The present invention easily and efficiently provides a peroxisome proliferator-activated receptor ligand, and a composition for amelioration of insulin resistance or for prevention and/or amelioration of the insulin resistance syndrome containing the same, as an active ingredient. | 2009-02-05 |
20090036520 | Combinations of vasoprotective agents and formulations containing them - Combinations of vasoprotective agents useful for the prevention and the treatment of vascular injuries induced by an excess of plasma lipids comprising polycosanols, tocotriends and/or lycopene, procyanidole oligomers and vegetable oil rich in insaturated fatty acids. | 2009-02-05 |
20090036521 | Process for Production of Optically Active Amine Derivatives - An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture. | 2009-02-05 |
20090036522 | Tablet Containing Hardly Soluble Active Ingredient - A tablet showing regulated variation in dissolution from lot to lot which contains from about 3 to about 50% by weight (w/w), based on the whole tablet, of (S)—N—[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, magnesium stearate and hydroxypropylcellulose having a viscosity of about 1 to about 4 mPa·s. | 2009-02-05 |
20090036523 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME - Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders. | 2009-02-05 |
20090036524 | TRITERPENE DERIVATIVES FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE BY INHIBITION OF NF-KAPPAB - The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF- | 2009-02-05 |
20090036525 | Non-Natural Amino Acid Derivatives - Compounds of formula (I) have activity in alleviating the effects of impaired dopaminergic signaling, for example in the treatment of Parkinsons Disease: | 2009-02-05 |
20090036526 | CRYSTAL OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE 1/4 HYDRATE - The present invention provides ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride ¼ hydrate or a crystal thereof which can be determined by characteristic diffraction peaks of the powder X-ray diffraction, thermogravimetry-differential thermal analysis or the like, and obtained by manufacturing ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method. | 2009-02-05 |
20090036527 | Therapeutic Application Of Leonurine In Treating Cardiomyopathy - The present invention provides methods for treating ischemic cardiomyopathy. In one embodiment, provided is a method of treating a disease characterized as ischemic cardiomyopathy, comprising administering to a subject suffering from said disease a pharmaceutical composition comprising therapeutically effective amount of synthesized Leonurine. The method induces at least one biochemical change to improve hypoxia myocardial cells survive rate, reduce LDH releasing from the ischemic myocardial cells, and reduce infarction area of cardiomyopathy in the subject. | 2009-02-05 |
20090036528 | Multifunctional and combinational application of aspartame and or futhan - The present invention is an application, composition, and method of using a pharmaceutically effective amount of aspartame or its primary metabolite aspartyl-phenylalanine in systematic and periodic application or dose as an aspirin (NSAID) substitute, treatment for osteoporosis, and or topical treatment for Rosacea. | 2009-02-05 |
20090036529 | THERAPEUTIC AGENT FOR FUNCTIONAL BRAIN DISEASE - Provision of an agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same. | 2009-02-05 |
20090036530 | Crystalline acid of lipoxin A4 analogs and method of making - This invention is directed to a crystalline acid of a lipoxin A | 2009-02-05 |
20090036531 | Method for treatment of onychomycosis - Onychomycosis is treated by grinding the infected portion of a nail down to a level where the nail is not infected and applying a coating of a cyanoacrylate ester to the ground portion which cures to a hard layer. The hard layer can be successively ground and coated with successive layers of cycanoacrylate. | 2009-02-05 |
20090036532 | DHA Enrichment Process - The present invention relates to a continuous process of DHA enrichment of a solution of fatty acids or derivatives thereof comprising less than 50% of DHA relative to the total fatty acids of the solution or to derivatives thereof, wherein the process comprises the steps of (a) simultaneous countercurrent injection, into a fractionation column, of the flow of the solution of fatty acids or of derivatives thereof and of a flow of supercritical CO | 2009-02-05 |
20090036533 | ANTIBACTERIAL AGENT COMPRISING 7, 10-DIHYDROXY-8(E)-OCTADECENOIC ACID - The present invention relates to an antibacterial agent containing 7,10-dihydroxy-8(E)-octadecenoic acid (referred as DOD) as an active ingredient. DOD produced by the method of the present invention can be effectively used as an antibacterial agent because it has a wide spectrum of antibacterial activity against various microorganisms. | 2009-02-05 |
20090036534 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction - A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and a pharmaceutically acceptable carrier. | 2009-02-05 |
20090036535 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease - The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. | 2009-02-05 |
20090036536 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 2009-02-05 |
20090036537 | AROMATIC TRIAMIDE-LANTHANIDE COMPLEXES - The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention. | 2009-02-05 |
20090036538 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS - The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues. | 2009-02-05 |
20090036539 | STABLE HYPERBARIC COMPOSITION COMPRISING PRILOCAINE HCL, USE OF SAID NEW COMPOSITION FOR INTRATHECAL ANAETHESIA, AND METHOD FOR MANUFACTURING SAID COMPOSITION - The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15° C.-27° C.). The present invention also concerns a method for manufacturing said compositions. | 2009-02-05 |
20090036540 | Guanylhydrazones in Methods of Treatment or Diagnosis as Modulators of Signal Transduction - A method is provided for the treatment of a condition mediated by raf kinase, which includes administering a guanylhydrazone to a subject in need thereof. A method is also provided, which includes modulating or inhibiting signal transduction in a c-raf pathway with at least one guanylhydrazone. Another method is provided, which includes contacting one or more human mononuclear cells with at least one guanylhydrazone and at least one lipopolysaccharide to obtain one or more treated cells; contacting at least one selected from the group including said treated cells, one or more lysates thereof, and combinations thereof, with at least one surface-bound peptide in a surface-bound peptide array; and selectively modulating or inhibiting the phosphorylation of the surface-bound peptide. | 2009-02-05 |
20090036541 | Applicator and chemical combination for better topical anesthesia - One embodiment of a thin plastic applicator ( | 2009-02-05 |
20090036542 | Hydroquinone Long-Chain Derivative and/or Phenoxy Long-Chain Derivative and Pharmaceutical Comprising Same - The present invention provides compounds represented by formula (1) shown below: | 2009-02-05 |
20090036543 | Preservatives - The present invention relates to the use of compounds of the formula (1) wherein all substitutents have the meanings as defined in claim | 2009-02-05 |
20090036544 | METHODS AND COMPOSITIONS FOR INHIBITING THE PROLIFERATION OF PROSTATE CANCER CELLS - The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of POH, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with POH as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing POH in particular formulations, and POH with a second compound that also exerts an effect on the androgen receptor. | 2009-02-05 |
20090036545 | Skin appearance through gene manipulation - The present invention relates to a method for treating, preventing and improving the condition and/or aesthetic appearance of aging skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, through meroterpene induced gene manipulation. | 2009-02-05 |
20090036546 | Medicinal Oil Compositions, Preparations, and Applications Thereof - A medicinal white oil composition is prepared from an isomerized base oil. The isomerized base oil is filtered through a filter bed containing an acid activated clay having a surface area of at least 100 m | 2009-02-05 |
20090036547 | INSECTICIDAL COMPOSITION - The present invention relates to the use of a composition comprising cymene as a larvicide against mosquito larvae of a genus other than | 2009-02-05 |
20090036548 | Mascara and liquid eyeliner enhancer - A composition and method of use of a composition for enhancing the usability of eye cosmetics, including but not limited to mascara and liquid eyeliner. The composition and its formulation contains a liquid enhancer, such that a few drops of the liquid enhancer added to the mascara and/or liquid eyeliner are used to maintain the viscosity, consistency, and smoothness of the cosmetic at the levels of the original, newly provided cosmetic. This enhancement thus allows continued ease of use and longer useful life of the cosmetic material. | 2009-02-05 |
20090036549 | SUBSTANCE-ENCAPSULATED CARBON NANOHORN COMPLEX AND PRODUCING METHOD THEREOF - A cap of polyamine molecules is provided on an aperture portion of carbon nanohorns having apertures formed by oxidation. The polyamine cap opens and closes according to the pH of the ambient environment, thereby controlling release of an encapsulation substance. | 2009-02-05 |
20090036550 | Copolymers Based on Polyalkylene Oxide-Modified N-Vinyl Lactam Copolymers - Vinyllactam copolymers modified with polyalkylene oxide side-chains, and use thereof as solubilizers for substances which are sparingly soluble in water, and preparations comprising such copolymers. | 2009-02-05 |
20090036551 | COPOLYMERS BASED ON N-VINYL LACTAMS AND OLEFINS AS THEIR USE AS SOLUBILIZERS FOR SLIGHTLY WATER-SOLUBLE COMPOUNDS - The use of copolymers obtained by free-radical polymerization of a mixture of | 2009-02-05 |
20090036552 | Noninvasive Drug Delivery System To Tissue of Posterior Segment of Eye Using Solid Composition - The present invention provides a drug delivery system by noninvasive administration, which is excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue. By administering a solid composition comprising a drug and a mucoadhesive substance having an adhesion strength of from 200 to 1000 g in the conjunctival sac, a drug delivery system excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue can be constructed. | 2009-02-05 |
20090036553 | DENDRITIC ENCAPSULATION OF ACTIVE AGENTS - A pharmaceutical composition comprising an active agent bound to a scaffold for dendritic encapsulation wherein said scaffold is covalently or non-covalently attached to a polysaccharide. More specifically, the invention is directed to active agent complexes or conjugates which utilize dendritic encapsulation alone or in combination with other delivery systems to improve and target active agent release. | 2009-02-05 |
20090036554 | OPHTHALMIC COMPOSITIONS COMPRISING A TERPENE COMPOUND - An aqueous ophthalmic composition comprising one or more terpene compounds, and one or more natural polymers selected from the group comprising hyaluronic acid, condroitin sulfate, alginate, guar gum, fructan, arabinogalactan or any corresponding salt or derivative of each thereof. The compositions can be used to disinfect or package a contact lens, or as an eye drop to comfort irritated eyes or rewet a contact lens. | 2009-02-05 |
20090036555 | Stabilization of iodine biocides - 2-(2-Hydroxyphenyl)benzotriazoles are outstandingly suitable for stabilizing iodine-containing biocides in industrial materials, more particularly in paints based on alkyd resin. | 2009-02-05 |
20090036556 | Acidic Zirconia Sol and Production Method of the Same - There is provided an acidic zirconia sol having compatibility of particle properties and binding properties, and a production method of the same. | 2009-02-05 |
20090036557 | PRODUCTION OF AEROGELS CONTAINING FILLERS - The invention relates to a method for producing an aerogel that contains a filler and has an extremely low thermal conductivity. The aerogel moulded body contains an inorganic filler with a thermal conductivity of up to 0.5 Wm | 2009-02-05 |
20090036558 | Modified catalyst and use of this catalyst for the conversion of synthesis gas to hydrocarbons - The present invention relates to a process for the conversion of synthesis gas to hydrocarbons in the presence of a modified supporter Fischer-Tropsch catalyst composition. | 2009-02-05 |
20090036559 | POROUS MONODISPERSED PARTICLES AND METHOD FOR PRODUCTION THEREOF, AND USE THEREOF - To provide porous monodispersed particles obtained by preparing, as seed particles, poly(methyl methacrylate) particles or acrylic resin particles comprising 70% by mass or more of methyl methacrylate as a copolymerization component, swelling the seed particles 20 to 80 times the size of the original seed particles by mass using a swelling solution comprising an oil-soluble polymerization initiator and a monomer mixture containing 70% by mass or more of methyl methacrylate and 3 to 8% by mass of divinylbenzene, and polymerizing the monomers. The particles are porous particles with a diameter of the order of micrometers and a narrow particle-size distribution and are monodispersed. Colored monodispersed particles obtained by agglomerating a pigment in the porous monodispersed particles are monodispersed and spherical, and contain a large amount of pigment therein. | 2009-02-05 |
20090036560 | FOAMING COMPOSITION - A foaming composition is provided, which includes water, pulp, alginic ester, and a surfactant. A preferable example of the alginic ester is propylene glycol alginate. The alginic ester may be mixed therein at a mixing amount ranging from 5 parts by weight to 15 parts by weight based on 100 parts by weight of the pulp. | 2009-02-05 |
20090036561 | FIRE-RESISTANT COMPOSITION FOR COATING, SEALING AND PROTECTION PURPOSES - The present invention relates to a fire-resistant composition for coating, filling, sealing, and protection comprising an isocyanate curable polymer, a polymer curable isocyanate, an aliphatic polyether glycol, and rubber, whereby it further comprises ammonium polyphosphate, expanding graphite, and aluminum trihydrate. | 2009-02-05 |
20090036562 | Process for preparing closed-cell water-blown rigid polyurethane foams having improved mechanical properties - The present invention is directed to a process for preparing water-blown rigid polyurethane foams having at least an 80% closed-cell content which involves reacting a) at least one polyol mixture which is composed of (i) at least one polymer polyol; (ii) at least one polyol having a hydroxyl value within the range of from about 200 to about 800; and (iii) optionally, at least one polyol having a hydroxyl value within the range of from about 25 to about 115; with b) at least one polymeric isocyanate and/or a prepolymer thereof; in the presence of c) optionally, at least one catalyst; d) water; and e) optionally, at least one additive or auxiliary agent. The present invention is also directed to the closed-cell water blown rigid polyurethane foams produced by the process of the present invention. The invention is further directed to a polyurethane-foam forming mixture which is used to produce the water-blown rigid polyurethane foams of the present invention. Foams produced according to the present invention have reduced friability and acceptable adhesion to substrates as well as acceptable compressive strength. | 2009-02-05 |
20090036563 | POLYMER BLEND FOR PRODUCING SHAPE-MEMORY FOAM, FOAM THEREOF AND METHOD FOR PRODUCING THE FOAM - A shape-memory polymer foam is disclosed, which is formed by kneading a shape-memory copolyester with a polymeric material having a relatively lower crystallinity in a weight ratio of 15:85 to 85:15 and then conducting a foaming process. The shape-memory copolyester is a random copolymer formed from a dicarboxylic acid mixture and a diol in excess through esterfication and polycondensation. The dicarboxylic acid mixture includes 30-99 mol % of an aromatic dicarboxylic acid and 70-1 mol % of a straight aliphatic dicarboxylic acid of C | 2009-02-05 |
20090036564 | Bio-Degenerable Bone Cement and Manufacturing Method thereof - A bio-degenerable bone cement is made of a mixture of poly (propylene fumarate) (PPF) and a diphasic material of tetra-calcium phosphate (TTCP)/dicalcium phosphate anhydrous (DCPA). The bone cement produced by a manufacturing method is injectable, bio-degenerable and non-penetrable to radioactive rays and features the advantages of a compressive strength close to the strength of bones, a low polymerization temperature, and a high biological compatibility. | 2009-02-05 |
20090036565 | Dental Composites with a Low Shrinkage Tension and High Flexural Strength - Dental composite materials based on (meth)acrylate, exhibiting a proportion of TCD monomers in the total composition of 1-15% by weight and the quotient of flexural strength/shrinkage tension is at least 35. | 2009-02-05 |
20090036566 | BIODEGRADABLE COMPOSITE, PRODUCT MADE THEREFROM, AND METHOD OF MANUFACTURE THEREOF - Biodegradable composites and products, and methods of their manufacture are presented. The composites typically comprise 10 wt % to 80 wt % of a lignocellulosic material derived from an agricultural residue or obtained from a natural source, 20 wt % to 80 wt % of a polymer binder, 5 wt % to 20 wt % of a compatibilizer, and an effective amount of a processing aid. One method of manufacture of a product is by injection molding. | 2009-02-05 |
20090036567 | PROCESS FOR PRODUCING MODIFIED DIENE POLYMER RUBBER - There is provided a process for producing a modified diene polymer rubber comprising the steps of:
| 2009-02-05 |
20090036568 | SELF HEALING COMPOSITE MATERIAL AND METHOD OF MANUFACTURING SAME - A self-healing material comprises a matrix embedded with micro-pockets of a healing-agent releasable by a crack in the matrix. The healing-agent is able to bond to the matrix to repair the crack. The healing-agent is contained in microcapsules. A corresponding catalyst for the healing-agent is embedded in the matrix and contained in a plurality of microcapsules as an emulsion. The emulsion comprises an oil, a perfluorated solvent, a hydrophobic ionic liquid, or mixtures thereof. A method of manufacturing the self-healing material comprises the steps of identifying an operational temperature range of the material, providing at least one substance as the healing-agent, which substance remaining substantially in a liquid state within the operational temperature range, identifying an operational evaporation rate of the healing-agent and providing the substance with a curing time according to the evaporation rate. | 2009-02-05 |
20090036569 | Process For Recycling Polymeric Waste Materials - The present invention provides a process which utilizes biodiesel and other high boiling esters containing short alkyl groups to produce liquid fuels from fluff. The fluff is added to a solvent having a predetermined cycle starting solvent volume. An energy source is introduced into the solvent for a predetermined time at a predetermined temperature and pressure to form a product. The energy source is removed and the product is cooled to a predetermined temperature to produce the fuel. The invention also encompasses the fuel formed by the process described. | 2009-02-05 |